Innate and adaptive T cells in asthmatic patients: Relationship to severity and disease mechanisms

Background Asthma is a chronic inflammatory disease involving diverse cells and mediators whose interconnectivity and relationships to asthma severity are unclear. Objective We performed a comprehensive assessment of TH17 cells, regulatory T cells, mucosal-associated invariant T (MAIT) cells, other T-cell subsets, and granulocyte mediators in asthmatic patients. Methods Sixty patients with mild-to-severe asthma and 24 control subjects underwent detailed clinical assessment and provided induced sputum, endobronchial biopsy, bronchoalveolar lavage, and blood samples. Adaptive and invariant T-cell subsets, cytokines, mast cells, and basophil mediators were analyzed. Results Significant heterogeneity of T-cell phenotypes was observed, with levels of IL-13–secreting T cells and type 2 cytokines increased at some, but not all, asthma severities. TH17 cells and γδ-17 cells, proposed drivers of neutrophilic inflammation, were not strongly associated with asthma, even in severe neutrophilic forms. MAIT cell frequencies were strikingly reduced in both blood and lung tissue in relation to corticosteroid therapy and vitamin D levels, especially in patients with severe asthma in whom bronchoalveolar lavage regulatory T-cell numbers were also reduced. Bayesian network analysis identified complex relationships between pathobiologic and clinical parameters. Topological data analysis identified 6 novel clusters that are associated with diverse underlying disease mechanisms, with increased mast cell mediator levels in patients with severe asthma both in its atopic (type 2 cytokine–high) and nonatopic forms. Conclusion The evidence for a role for TH17 cells in patients with severe asthma is limited. Severe asthma is associated with a striking deficiency of MAIT cells and high mast cell mediator levels. This study provides proof of concept for disease mechanistic networks in asthmatic patients with clusters that could inform the development of new therapies.

[1]  D. Robinson,et al.  Resolution of airway inflammation and hyperreactivity after in vivo transfer of CD4+CD25+ regulatory T cells is interleukin 10 dependent , 2005, The Journal of experimental medicine.

[2]  P. Howarth,et al.  Potentially Pathogenic Airway Bacteria and Neutrophilic Inflammation in Treatment Resistant Severe Asthma , 2014, PloS one.

[3]  R. Djukanović,et al.  Invariant natural killer T cells in asthma and chronic obstructive pulmonary disease. , 2007, The New England journal of medicine.

[4]  K. Bracke,et al.  Eosinophils in the Spotlight: Eosinophilic airway inflammation in nonallergic asthma , 2013, Nature Medicine.

[5]  M. Toda,et al.  Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. , 1995, Journal of immunology.

[6]  R. Coffman,et al.  Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. , 1986, Journal of immunology.

[7]  J. Alcorn,et al.  TH17 Cells Mediate Steroid-Resistant Airway Inflammation and Airway Hyperresponsiveness in Mice1 , 2008, The Journal of Immunology.

[8]  P. Y. Lum,et al.  Extracting insights from the shape of complex data using topology , 2013, Scientific Reports.

[9]  Malcolm J. McConville,et al.  MR1 presents microbial vitamin B metabolites to MAIT cells , 2012, Nature.

[10]  M. Kronenberg,et al.  CD1d-mediated Recognition of an α-Galactosylceramide by Natural Killer T Cells Is Highly Conserved through Mammalian Evolution , 1998, The Journal of experimental medicine.

[11]  S. Durham,et al.  Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. , 1992, The New England journal of medicine.

[12]  Q. Hamid,et al.  IL-17 is increased in asthmatic airways and induces human bronchial fibroblasts to produce cytokines. , 2001, The Journal of allergy and clinical immunology.

[13]  M. Leinonen,et al.  Risk of invasive pneumococcal infections among working age adults with asthma , 2010, Thorax.

[14]  R. Djukanović,et al.  Phenotypic characterization of lung macrophages in asthmatic patients: overexpression of CCL17. , 2012, The Journal of allergy and clinical immunology.

[15]  W. Schaffner,et al.  Asthma as a risk factor for invasive pneumococcal disease. , 2005, The New England journal of medicine.

[16]  J. Bousquet,et al.  Eosinophilic inflammation in asthma. , 1990, The New England journal of medicine.

[17]  S. Durham,et al.  Tregs and allergic disease. , 2004, The Journal of clinical investigation.

[18]  M. Humbert,et al.  A proof-of-concept, randomized, controlled trial of omalizumab in patients with severe, difficult-to-control, nonatopic asthma. , 2013, Chest.

[19]  R. Pauwels,et al.  GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND PREVENTION , 1996 .

[20]  Nicola A Hanania,et al.  Lebrikizumab treatment in adults with asthma. , 2011, The New England journal of medicine.

[21]  A. Magnan,et al.  T‐cell activation during exacerbations: a longitudinal study in refractory asthma , 2008, Allergy.

[22]  S. Willsie.  Mepolizumab and Exacerbations of Refractory Eosinophilic Asthma , 2010 .

[23]  S. Durham,et al.  Identification of activated T lymphocytes and eosinophils in bronchial biopsies in stable atopic asthma. , 1990, The American review of respiratory disease.

[24]  Ana Sousa,et al.  Mepolizumab and exacerbations of refractory eosinophilic asthma. , 2009, The New England journal of medicine.

[25]  E. Kerwin,et al.  Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma. , 2013, American journal of respiratory and critical care medicine.

[26]  G. Anderson,et al.  Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease , 2008, The Lancet.

[27]  P. Gibson,et al.  Airway mast cells and eosinophils correlate with clinical severity and airway hyperresponsiveness in corticosteroid-treated asthma. , 2000, Journal of Allergy and Clinical Immunology.

[28]  S. Wenzel,et al.  Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. , 1999, American journal of respiratory and critical care medicine.

[29]  P. Hellings,et al.  IL-17 mRNA in sputum of asthmatic patients: linking T cell driven inflammation and granulocytic influx? , 2006, Respiratory research.

[30]  D. Curran‐Everett,et al.  Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. , 2010, American journal of respiratory and critical care medicine.

[31]  A. Rudensky,et al.  Foxp3 programs the development and function of CD4+CD25+ regulatory T cells , 2003, Nature Immunology.

[32]  Mike Thomas,et al.  Cluster analysis and clinical asthma phenotypes. , 2008, American journal of respiratory and critical care medicine.

[33]  W. Busse,et al.  Mast cell phenotype, location, and activation in severe asthma. Data from the Severe Asthma Research Program. , 2011, American journal of respiratory and critical care medicine.

[34]  Michael Mitzenmacher,et al.  Detecting Novel Associations in Large Data Sets , 2011, Science.

[35]  P. Sterk,et al.  Standardised methodology of sputum induction and processing , 2002, European Respiratory Journal.

[36]  R. Scott,et al.  Inflammatory subtypes in asthma: Assessment and identification using induced sputum , 2006, Respirology.

[37]  M. Piccinni,et al.  Allergen- and bacterial antigen-specific T-cell clones established from atopic donors show a different profile of cytokine production. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[38]  I. Pavord,et al.  Increased sputum and bronchial biopsy IL-13 expression in severe asthma. , 2008, The Journal of allergy and clinical immunology.

[39]  Gunnar E. Carlsson,et al.  Topology and data , 2009 .

[40]  E. Juniper,et al.  Measuring asthma control. Clinic questionnaire or daily diary? , 2000, American journal of respiratory and critical care medicine.

[41]  J. Banchereau,et al.  T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines , 1996, The Journal of experimental medicine.

[42]  S. Wenzel,et al.  Relationship of small airway chymase-positive mast cells and lung function in severe asthma. , 2005, American journal of respiratory and critical care medicine.

[43]  I. Pavord,et al.  Mast-cell infiltration of airway smooth muscle in asthma. , 2002, The New England journal of medicine.

[44]  W. Busse,et al.  Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. , 2001, The Journal of allergy and clinical immunology.

[45]  Charles Auffray,et al.  An integrative systems biology approach to understanding pulmonary diseases. , 2010, Chest.

[46]  A. Kay,et al.  Quantitation of mast cells and eosinophils in the bronchial mucosa of symptomatic atopic asthmatics and healthy control subjects using immunohistochemistry. , 1991, The American review of respiratory disease.

[47]  S. Cowley,et al.  MAIT cells are critical for optimal mucosal immune responses during in vivo pulmonary bacterial infection , 2013, Proceedings of the National Academy of Sciences.

[48]  O. Lantz,et al.  Human MAIT cells are xenobiotic-resistant, tissue-targeted, CD161hi IL-17-secreting T cells. , 2011, Blood.

[49]  Adnan Custovic,et al.  Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. , 2011, The Journal of allergy and clinical immunology.